Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease

Figure 1 Elafibranor on steatohepatitis and lipid accumulation in the alcohol-associated liver disease mice. A: In vivo experimental design; B: Changes in the body weights during the experimental period (n = 10); C: Liver/body weight at the end of experiment (n = 10); D: Serum levels of aspartate aminotransferase, alanine aminotransferase and gamma glutamyl transferase (n = 10); E: Serum triglyceride level (n = 10); F: Representative microphotographs of hematoxylin and eosin of the livers in the experimental mice; G: Hepatic pathological scores for steatosis and inflammation. Localized magnified images in the lower left corner of each picture (n = 10); H: Hepatic triglyceride content; I: Hepatic free fatty acid concentration (n = 10); J-L: Hepatic mRNA level of the markers related to lipogenesis (J), lipolysis (K), fatty acid oxidation (L) (n = 10). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control for real-time quantitative polymerase chain reaction. Quantitative values are indicated as fold changes to the values of non-therapeutic group. Data are the mean ± SD. ^bP < 0.01 vs non-therapeutic group; ^cP < 0.05 vs vehicle-treated alcohol-associated liver disease group; ^dP < 0.01 vs vehicle-treated alcohol-associated liver disease group, significant difference between groups by Student’s t-test. NT: Non-therapeutic group; Veh: Vehicle-treated alcohol-associated liver disease group; EFN-L: Elafiblanor (3 mg/kg/day)-treated alcohol-associated liver disease group; EFN-H: Elafibranor (10 mg/kg/day)-treated alcohol-associated liver disease group; NLD: Normal liquid diet; EtOH: Ethanol; CCL₄: Carbon tetrachloride; EFN: Elafiblanor; Lw: Liver weight; Bw: Body weight; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; TG: Triglyceride; H&E: Hematoxylin and eosin; FFA: Free fatty acid; FA: Fatty acid.